DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20175203

Effect of methyldopa and labetolol on fetal outcomes in hypertensive disorders of pregnancy

Mary Rohini Pentareddy, Shailendra D.

Abstract


Background: Hypertensive disorders represent the most common medical complication of pregnancy, with a reported incidence of 6-10% and accounts for 15% of maternal mortality. Effective management of pregnancy induced hypertension is vital to improve maternal and foetal outcomes. As data are scarce on comparison of labetolol and methyldopa this study was undertaken. The objectives of the study were to evaluate effect of both drugs on fetal outcomes.

Methods: A comparative observational Study is designed. 30 patients who received Methyldopa and 30 patients who received Labetolol were included in the study. Methyldopa was started at a dose of 250-500mg thrice daily while Labetolol was started at a dose of 100-400mg twice daily. Patients were followed up during antenatal, intrapartum and postpartum period for perinatal outcomes.

Results: Intra Uterine Growth Retarded (IUGR) babies were 10% in Methyldopa group and 6.66% in Labetolol group. 20% of new borns in Methyldopa group and 10% of new borns in Labetolol group got admitted in Neonatal Intensive Care Unit (NICU) because of distress. 13.3% of new borns in Methyldopa group are small for gestational age(SGA), whereas only 3.33% in Labetolol group are small for gestational age.

Conclusions: Chances of development of IUGR, NICU admissions of neonates with respiratory distress syndrome and small for gestational age babies were more with methyldopa compared to Labetolol, but there was no statistically significant difference between two drugs.


Keywords


Fetal side effects, Labetolol, Methyldopa, PIH

Full Text:

PDF

References


National High Blood Pressure Education Program: Working Group Report on High Blood Pressure in Pregnancy. Ame J of Obs & Gyn. 2000;183:51.

Cochrane study group Magee L, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews. 2003;3:CD002863.

Goodman & Gilman’s the pharmacological basis of therapeutics; 11th Ed. 2006:32.

El-Qarmalawi AM, Morsy AH, Al-Fadly A, Obeid A, Hashem M. Labetolol vs Methyldopa in the treatment of pregnancy-induced hypertension. Int J of Gyn& Obs. 1995;49:125-30.

Verma R, Lahon K, Tonpay SD, Kale VJ, Jain DK. A comparative randomised controlled parallel group study of efficacy and tolerability of Labetolol versus Methyldopa in the treatment of new onset hypertension during pregnancy. International Journal of Life Science & Pharma Research. 2012;2(1).

Plouin PF, Breart G, Maillard F, Papiernik E, Relier JP. The Labetolol Methyldopa Study Group. Comparison of antihypertensive efficacy and perinatal safety of Labetolol and Methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial. British J of Obs and Gyn. 1988;95:868-76.

Lamming GD, Symonds EM. Use of Labetolol and Methyldopa in pregnancy induced hypertension. British J of Cli Pha. 1979;8:217S-22S.

Molvi SN, Mir S, Rana VS, Jabeen F, Malik AR. Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing Labetolol with methyldopa. Archives of Gynecology and Obstetrics. 2012;285(6):1553-62.

Pickles CJ, Symonds EM, Pipkin FB. The fetal outcome in a randomized double-blind controlled trial of Labetolol versus placebo in pregnancy-induced hypertension. British J of Obs & Gyn.1989;96:38-43.

Walker JJ, Crooks A, Erwin L, Calder AA. Labetolol in pregnancy induced hypertension. Fetal and maternal effects. In: Riley and Symmonds (eds). The investigation of Labetolol in the management of hypertension in pregnancy. Excerpta medica, Amsterdam. 1982:148-60.